Multiple Sclerosis Research
Study Title: A 12 month, Randomized, rater- and dose-blinded study to compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 Administered Orally Once Daily in patients with Relapsing-Remitting Multiple Sclerosis (Identifier: NCT01633112)
Study Purpose: The purpose of this study is to compare 2 doses (0.25 mg and 0.50 mg) of fingolimod to glatiramer acetate (20 mg) and to evaluate the efficacy of fingolimod 0.25 mg for the treatment of patients with relapsing-remitting MS (RRMS).
Principal Investigator: Boyd Koffman, MD
Study Coordinator: Andrea Korsnack, for more information, please call at 419-383-3801.